NYSE:AMRX 23 December 2025 - 8 January 2026

Amgen shares rose 3.5% to $341.64 after UBS initiated coverage with a buy rating and a $380 target. The move follows FDA approval of Amneal’s biosimilar rivals to Amgen’s Prolia and Xgeva, which generated $5.3 billion in U.S. sales last year. Amgen also announced an $840 million deal to acquire Dark Blue Therapeutics, adding an early-stage leukemia drug. CEO Robert Bradway will present at the J.P. Morgan Healthcare Conference on Jan. 12.

The FDA approved new denosumab biosimilars referencing Amgen’s Prolia and XGEVA after markets closed Monday. Amgen shares ended the day up 1.2% at $331.39. Fitch upgraded Amgen’s credit rating to BBB+ with a stable outlook. Post-market trading showed little immediate reaction.